title: Entering the new era of therapy for HBV and HCV infections.
authors.affiliation: University of California, San Francisco, San Francisco, California, USA.
authors.forename: Marion G
authors.initials: MG
authors.lastname: Peters
authors.forename: Robert P
authors.initials: RP
authors.lastname: Perrillo
authors.forename: Ira M
authors.initials: IM
authors.lastname: Jacobson
authors.forename: David B
authors.initials: DB
authors.lastname: Ross
authors.forename: Edward C
authors.initials: EC
authors.lastname: Doo
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Murray
authors.forename: John B
authors.initials: JB
authors.lastname: Wong
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D018579:Patient Selection; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D011994:Recombinant Proteins; D012254:Ribavirin; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a